Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ONCOLOGY / CLINICAL RESEARCH
lncRNA EGOT across cancers: TCGA analysis
1
Greater Poland Cancer Center, Research and Implementation Unit, Poznan, Poland
2
Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland
3
Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Poznan, Poland
4
Microbiology Laboratory, Greater Poland Cancer Centre, Poznan, Poland
5
Chair and Department of Cell Biology, Poznan University of Medical Sciences, Poznan, Poland
6
Radiation Protection Department, Greater Poland Cancer Centre, Poznan, Poland
7
Department of Tumor Pathology and Prophylaxis, Greater Poland Cancer Center, Poznan, Poland
8
Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland
9
Department of Diagnostics and Cancer Immunology, Poznan, Poland
10
Department of Laboratory Diagnostics, Greater Poland Cancer Centre, Poznan, Poland
11
Department of Tumor Pathology and Prophylaxis, Poznan University of Medical Sciences, Poznan, Poland
12
Department of Clinical Oncology, Greater Poland Cancer Center, Poznan, Poland
13
Electroradiology Department, University of Medical Sciences, Poznan, Poland, Poland
14
Radiotherapy Department II, Greater Poland Cancer Center, Poznan, Poland
Submission date: 2024-08-07
Final revision date: 2025-05-07
Acceptance date: 2025-06-01
Online publication date: 2025-08-19
Corresponding author
Tomasz Kolenda
Greater Poland Cancer Center Research and Implementation Unit Garbary Street 15 61-866 Poznan, Poland
Greater Poland Cancer Center Research and Implementation Unit Garbary Street 15 61-866 Poznan, Poland
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Long-non-coding RNAs (lncRNAs) are emerging as important regulators in the epigenetic control of cellular phenotypes. Among them, the eosinophil granule ontogeny transcript (EGOT) has attracted attention, as changes in its expression levels are correlated with pathological conditions, including tumorigenesis and viral infections. Despite many studies, the biological role and diagnostic utility of EGOT remain unclear.
Material and methods:
EGOT was analyzed based on the TCGA, including pathological and clinical features, cellular pathways, and genomic and cellular changes.
Results:
We observed an association of higher EGOT expression with better survival in breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), and kidney renal clear cell carcinoma (KIRC), as well as worse patient survival for liver hepatocellular carcinoma (LIHC). Expression levels of EGOT differ in the case of HNSC, KIRC, and LIHC. Critical cellular pathways and processes vary depending on the EGOT. Moreover, immune profile, cancer subtypes, and differences in the proliferation, wound healing ability, stromal fraction, and intratumor heterogeneity were observed in relation to these lncRNA levels, with the most pronounced differences seen mostly for BRCA and KIRC.
Conclusions:
EGOT seems to be a potential prognostic biomarker in clinical use. Possible factors that connect all of the analyzed types of cancers and changes in EGOT expression are viral activity and immunological response to viral infection.
Long-non-coding RNAs (lncRNAs) are emerging as important regulators in the epigenetic control of cellular phenotypes. Among them, the eosinophil granule ontogeny transcript (EGOT) has attracted attention, as changes in its expression levels are correlated with pathological conditions, including tumorigenesis and viral infections. Despite many studies, the biological role and diagnostic utility of EGOT remain unclear.
Material and methods:
EGOT was analyzed based on the TCGA, including pathological and clinical features, cellular pathways, and genomic and cellular changes.
Results:
We observed an association of higher EGOT expression with better survival in breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), and kidney renal clear cell carcinoma (KIRC), as well as worse patient survival for liver hepatocellular carcinoma (LIHC). Expression levels of EGOT differ in the case of HNSC, KIRC, and LIHC. Critical cellular pathways and processes vary depending on the EGOT. Moreover, immune profile, cancer subtypes, and differences in the proliferation, wound healing ability, stromal fraction, and intratumor heterogeneity were observed in relation to these lncRNA levels, with the most pronounced differences seen mostly for BRCA and KIRC.
Conclusions:
EGOT seems to be a potential prognostic biomarker in clinical use. Possible factors that connect all of the analyzed types of cancers and changes in EGOT expression are viral activity and immunological response to viral infection.
REFERENCES (51)
1.
Kozłowska J, Kolenda T, Poter P, et al. Long intergenic non-coding RNAs in HNSCC: from “Junk DNA” to important prognostic factor. Cancers 2021; 13: 2949.
2.
Guglas K, Kozłowska-Masłoń J, Kolenda T, et al. Midsize noncoding RNAs in cancers: a new division that clarifies the world of noncoding RNA or an unnecessary chaos? Rep Pract Oncol Radiother 2022; 27: 1077-93.
3.
Kolenda T, Paszkowska A, Braska A, et al. Host gene and its guest: short story about relation of long-noncoding MIR31HG transcript and microRNA miR-31. Rep Pract Oncol Radiother 2023; 28: 114-34.
4.
Guglas K, Bogaczyńska M, Kolenda T, et al. lncRNA in HNSCC: challenges and potential. Contemp Oncol 2017; 21: 259-66.
5.
Kozłowska-Masłoń J, Guglas K, Paszkowska A, et al. Radio-lncRNAs: biological function and potential use as biomarkers for personalized oncology. J Pers Med 2022; 12: 1605.
6.
Kolenda T, Kopczyńska M, Guglas K, et al. EGOT lncRNA in head and neck squamous cell carcinomas. Pol J Pathol 2018; 69: 356-65.
7.
Nema R. An omics-based tumor microenvironment approach and its prospects. Rep Pract Oncol Radiother 2024; 29: 649-50.
8.
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-14.
9.
Roszkowski S, Durczyńska Z, Szablewska S. Targeted nanodelivery systems for personalized cancer therapy. Rep Pract Oncol Radiother 2025; 29: 776-88.
10.
Wagner LA, Christensen CJ, Dunn DM, et al. EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression. Blood 2007; 109: 5191-8.
11.
Rose D, Stadler PF. Molecular evolution of the non-coding eosinophil granule ontogeny transcript. Front Genet 2011; 2: 69.
12.
Xu S, Wang P, Zhang J, et al. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol Cancer 2019; 18: 89.
13.
Qiu S, Chen G, Peng J, et al. LncRNA EGOT decreases breast cancer cell viability and migration via inactivation of the Hedgehog pathway. FEBS Open Bio 2020; 10: 817-26.
14.
Xu SP, Zhang JF, Sui SY, et al. Downregulation of the long noncoding RNA EGOT correlates with malignant status and poor prognosis in breast cancer. Tumour Biol 2015; 36: 9807-12.
15.
Jiao Y, Li S, Wang X, et al. A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer. Front Immunol 2022; 13: 929846.
16.
Lv W, Wang Y, Zhao C, et al. Identification and validation of m6A-related lncRNA signature as potential predictive biomarkers in breast cancer. Front Oncol 2021; 11: 745719.
17.
Peng W, Wu J, Fan H, Lu J, Feng J. LncRNA EGOT promotes tumorigenesis via hedgehog pathway in gastric cancer. Pathol Oncol Res 2019; 25: 883-7.
18.
Jin L, Quan J, Pan X, et al. Identification of lncRNA EGOT as a tumor suppressor in renal cell carcinoma. Mol Med Rep 2017; 16: 7072-9. Erratum in: Mol Med Rep 2024; 29: PMID: 28901455.
19.
Wu Y, Liang S, Xu B, et al. Long noncoding RNA eosinophil granule ontogeny transcript inhibits cell proliferation and migration and promotes cell apoptosis in human glioma. Exp Ther Med 2017; 14: 3817-23.
20.
Li C, Liu H, Wei R, et al. LncRNA EGOT/miR-211-5p affected radiosensitivity of rectal cancer by competitively regulating ErbB4. Onco Targets Ther 2021; 14: 2867-78.
21.
Ni Y, Li C, Bo C, et al. LncRNA EGOT regulates the proliferation and apoptosis of colorectal cancer by miR-33b-5p/CROT axis. Biosci Rep 2020 May 6: BSR20193893. doi: 10.1042/BSR20193893.
22.
Wang M, Wei Z, Wang S, Feng W, Shang L, Sun X. Long non-coding RNA EGOT is associated with 131iodine sensitivity and contributes to thyroid cancer progression by targeting miR-641/PTEN axis. Aging 2023; 15: 13542-57.
23.
Cui XF, Zhang SL, Wang WP, Huang XW, Chen XJ. Identification of competing endogenous RNA network in laryngeal squamous cell carcinoma. Oral Dis 2023; 29: 574-83.
24.
Zhang Y, Chen D, Yang M, Qian X, Long C, Zheng Z. Comprehensive analysis of competing endogenous RNA network focusing on long noncoding RNA involved in cirrhotic hepatocellular carcinoma. Anal Cell Pathol 2021; 2021: 5510111.
25.
Wang IK, Palanisamy K, Sun KT, et al. The functional interplay of lncRNA EGOT and HuR regulates hypoxia-induced autophagy in renal tubular cells. J Cell Biochem 2020; 121: 4522-34.
26.
Zhang C, Pan S, Aisha A, Abudoukelimu M, Tang L, Ling Y. Recombinant human brain natriuretic peptide regulates PI3K/AKT/mTOR pathway through lncRNA EGOT to attenuate hypoxia-induced injury in H9c2 cardiomyocytes. Biochem Biophys Res Commun 2018; 503: 1186-93.
27.
Zhao Q, Liu J, Ouyang X, et al. Role of immune-related lncRNAs--PRKCQ-AS1 and EGOT in the regulation of IL-1, IL-6 and IL-8 expression in human gingival fibroblasts with TNF- stimulation. J Dent Sci 2023; 18: 184-90.
28.
Greco S, Zaccagnini G, Perfetti A, et al. Long noncoding RNA dysregulation in ischemic heart failure. J Transl Med 2016; 14: 183.
29.
Barriocanal M, Prior C, Suarez B, et al. Long noncoding RNA EGOT responds to stress signals to regulate cell inflammation and growth. J Immunol 2021; 206: 1932-42.
30.
Carnero E, Barriocanal M, Prior C, et al. Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication. EMBO Rep 2016; 17: 1013-28.
31.
Sefatjoo Z, Mohebbi SR, Hosseini SM, et al. Evaluation of long non-coding RNAs EGOT, NRAV, NRIR and mRNAs ISG15 and IFITM3 expressions in COVID-19 patients. Cytokine 2024; 175: 156495.
32.
Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011; 146: 353-8.
33.
Kozłowska-Masłoń J, Guglas K, Kolenda T, Lamperska K, Makałowska I. miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology. Rep Pract Oncol Radiother 2023; 28: 681-97.
34.
Kolenda T, Śmiełowska MI, Lipowicz J, et al. The RNA world: from experimental laboratory to “in silico” approach. Part 1: User friendly RNA expression databases portals. Rep Pract Oncol Radiother 2024; 29: 245-57.
35.
Liu Y, Zhang B, Cao WB, Wang HY, Niu L, Zhang GZ. Study on clinical significance of LncRNA EGOT expression in colon cancer and its effect on autophagy of colon cancer cells. Cancer Manag Res 2020; 12: 13501-12.
36.
Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity 2018; 48: 812-30.e14. Erratum in: Immunity 2019; 51: 411-2.
37.
Kolenda T, Poter P, Guglas K, et al. Biological role and diagnostic utility of ribosomal protein L23a pseudogene 53 in cutaneous melanoma. Rep Pract Oncol Radiother 2023; 28: 255-70.
38.
Tomar S. Differential gene expression patterns in HPV-positive and HPV-negative oropharyngeal carcinomas. (Doctoral dissertation) 2013, Available online 2021.04.18; https://scholarcommons.sc.edu/....
39.
Li CX, Tan XR, Wei W, et al. A radiobiological perspective on radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma. Rep Pract Oncol Radiother 2024; 28: 809-22.
40.
Piwocka O, Musielak M, Piotrowski I, et al. Primary cancer-associated fibroblasts exhibit high heterogeneity among breast cancer subtypes. Rep Pract Oncol Radiother 2023; 28: 159-71.
41.
Jose SR, Timothy PB, Suganthy J, et al. Determination of dose-response calibration curves for gamma radiation using gamma-H2AX immunofluorescence based biodosimetry. Rep Pract Oncol Radiother 2024; 29: 164-75.
42.
Maćkowiak B, Ostrowska K, Kulcenty K, et al. The impact of XPC gene single nucleotide polymorphism rs2228001 on head and neck cancer patients’ response to radiotherapy treatment. Rep Pract Oncol Radiother 2024; 29: 148-54.
43.
Tanaka H, Ono T, Kajima M, et al. Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy. Rep Pract Oncol Radiother 2024; 29: 228-35.
44.
Malicki J, Piotrowski T, Guedea F, Krengli M. Treatment-integrated imaging, radiomics, and personalised radiotherapy: the future is at hand. Rep Pract Oncol Radiother 2022; 27: 734-43.
45.
Matuszak N, Piotrowski I, Kruszyna-Mochalska M, Skrobala A, Mocydlarz-Adamcewicz M, Malicki J. Monte Carlo methods to assess biological response to radiation in peripheral organs and in critical organs near the target. Rep Pract Oncol Radiother 2024; 29: 638-48.
46.
Alayón LF, Salas BS, Diaz-Saavedra RC, et al. Screening oropharyngeal dysphagia in patients with head and neck cancer in a radiation oncology department. Rep Pract Oncol Radiother 2024; 28: 756-63.
47.
Kolenda T, Białas P, Guglas K, et al. lncRNA EGOT is the marker of HPV infection and a prognostic factor for HNSCC patients. Biomedicines 2025; 13: 798.
48.
Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022; 19: 306-27.
49.
Sällberg M, Pasetto A. Liver, tumor and viral hepatitis: key players in the complex balance between tolerance and immune activation. Front Immunol 2020; 11: 552.
50.
Bersanelli M, Casartelli C, Buti S, Porta C. Renal cell carcinoma and viral infections: a dangerous relationship? World J Nephrol 2022; 11: 1-12.
51.
Afzal S, Fiaz K, Noor A, et al. Interrelated oncogenic viruses and breast cancer. Front Mol Biosci 2022; 9: 781111.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
